Denosumab, a monoclonal antibody against RANKL, is a promising treatment option for patients with spinal giant cell tumor of bone (GCTB), and has been approved by the United States Food and Drug Administration (FDA) [4]. The gene discussed is TNFSF11; the disease is bone giant cell tumor.